Sufferers of a painful and debilitating bladder disease have new hope thanks to an award from a charity which could help scientists at Newcastle University better understand their condition.
The Cystitis and Overactive Bladder Foundation is awarding £20,000 to academics at Newcastle University who are investigating a disorder known as Interstitial Cystitis (IC).
Most women have experienced the pain of cystitis, but for sufferers of IC the problem cannot be treated with a simple course of antibiotics. The disease, which affects an estimated 400,000 men and women in the UK, causes patients to feel constant pain in their bladder and they may pass water, often very urgently, up to 60 times a day. Drugs can help to manage the condition but there is no cure for IC, and patients can endure a lifetime of discomfort.
Scientists do not yet know why some people suffer with the disease, which can also cause inflammation and bleeding in the bladder, while others do not. But new research at Newcastle University into the role of so-called ‘bug busting’ chemicals known as antimicrobial peptides in IC may shed new light on the problem.
Professor Robert Pickard, Professor of Urology in the Institute of Cellular Medicine, and Dr Judith Hall who is leading the laboratory side of the research in the Institute for Cell and Molecular Biosciences, both at Newcastle University, are investigating the relative amounts of antimicrobial peptides (AMPs) in women with IC compared to those without painful bladder symptoms.
“We think that the way that antimicrobial peptides are activated in the bladder is not working correctly in people with Interstitial Cystitis,” said Dr Hall. “Our early results suggest these chemicals are being produced even where there is no bladder infection present.”
Professor Pickard added: “This may explain why so many patients describe their symptoms as being similar to cystitis even though they have no infection. It would seem their bladders are behaving as if there is an infection, causing all the associated pain and misery, even though they are infection-free.”
Further information may be found in the press release
published on: 14th December 2011